References
1. Zubin MB, Ronald PD. Updates on the management of gastrointestinal
stromal tumors. Surg Oncol Clin N Am . 2012;21(2):301-316.
2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA Activating
Mutations in Gastrointestinal Stromal Tumors. Science.2003;299(5607):708-710.
3. Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management
of gastrointestinal stromal tumors: before and after STI-571. Hum
Pathol . 2002;33(5):466-477.
4. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF.
Two hundred gastrointestinal stromal tumors: recurrence patterns and
prognostic factor for survival. Ann Surg . 2000;231(1):51-58.
5. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the
gastrointestinal stromal tumor model. Ann Surg .
2006;44(2):176-184.
6. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients
with gastrointestinal stromal tumour: a retrospective population
pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma
Group. Cancer Chemother Pharmacol . 2005;55(4):379-386.
7. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase
inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit
and platelet-derived growth factor receptors. J Pharmacol Exp
Ther . 2000;295(1):139-145.
8. Delbaldo C, Chatelut E, Ré M, et al. Pharmacokinetic-pharmacodynamic
relationships of imatinib and its main metabolite in patients with
advanced gastrointestinal stromal tumors. Clin Cancer Res .
2006;12(20):6073-6078.
9. Rutkowski P, Ziętek M, Cybulska-Stopa B, et al. The analysis of
3-year adjuvant therapy with imatinib in patients with high-risk
molecular profiled gastrointestinal stromal tumors (GIST) treated in
routine practice. Eur J Surg Oncol . 2021;47(5):1191-1195.
10. Li J, Gong JF, Wu AW, Shen L. Post-operative imatinib in patients
with intermediate or high risk gastrointestinal stromal tumor. Eur
J Surg Oncol . 2011;37(4):319-324.
11. Joensuu H, Eriksson M, Hall KS, et al. One vs three years of
adjuvant imatinib for operable gastrointestinal stromal tumor: a
randomized trial. JAMA . 2012;307(12):1265-72.
12. Qi J, Liu HL, Ren F, et al. Preoperative adjuvant therapy for
locally advanced and recurrent/metastatic gastrointestinal stromal
tumors: a retrospective study. World J Surg Oncol . 2020;18(1):70.
13. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and
molecular features correlate with long-term outcome after adjuvant
therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.J Clin Oncol. 2014;32(15):1563-70.
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of
imatinib mesylate in advanced gastrointestinal stromal tumors. N
Engl J Med . 2002;347:472-80.
15. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of
resistance to imatinib mesylate (IM) in advanced gastrointestinal
stromal tumor (GIST). Proc Am Soc Clin Oncol .
2003;22:3275.
16. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a
randomized phase II trial of standard- versus higher-dose imatinib
mesylate for patients with unresectable or metastatic gastrointestinal
stromal tumors expressing KIT. J Clin Oncol , 2008;26:620-625.
17. Xia YZ, Chen SL, Luo MJ, et al. Correlations Between Imatinib Plasma
Trough Concentration and Adverse Reactions in Chinese Patients with
Gastrointestinal Stromal Tumors. Cancer ,2020;126:2054-2061.
18. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are
correlated with clinical benefit in patients with
unresectable/metastatic gastrointestinal stromal tumors. J Clin
Oncol . 2009;27(19):3141-3147.
19. Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib
and its correlation with clinical response in the tyrosine kinase
inhibitor optimization and selectivity trial. Haematologica .
2012;97(5):731-738.
20. Li J, Ye Y, Wang J, et al. Chinese Society Of Clinical Oncology Csco
Expert Committee On Gastrointestinal Stromal Tumor. Chinese consensus
guidelines for diagnosis and management of gastrointestinal stromal
tumor. Chin J Cancer Res . 2017;29(4):281-293.
21. FDA [Internet]. Guidance for industry: bioanalytical method
validation; [cited May 24, 2018]. Available from: https://www.fda.
gov/downloads/drugs/guidances/ucm070107.Pdf. Accessed October 19, 2021.
22. Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic & clinical
pharmacology & toxicology policy for experimental and clinical studies.
Basic Clin Pharmacol Toxicol. 2018;123(3):233-235.
23. Bouchet S, Poulette S, Titier K, et al. Relationship between
imatinib trough concentration and outcomes in the treatment of advanced
gastrointestinal stromal tumours in a real-life setting. Eur J
Cancer . 2016,57:31-38.
24. Wu X, Li J, Zhou Y, et al. Relative Factors Analysis of Imatinib
Trough Concentration in Chinese Patients with Gastrointestinal Stromal
Tumor. Chemotherapy . 2018; 63(6): 301-307.
25. Koo DH, Ryu MH, Ryoo BY, et al. Association of ABCG2 polymorphism
with clinical efficacy of imatinib in patients withgastrointestinal
stromal tumor. Cancer Chemoth Pharm . 2015;75(1):173-182.
26. Lv M, Wu C, Zheng Y, Zhao NQ. Incidence and Survival Analysis of
Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study
from 2001 to 2010. Gastroent Res Pract. 2014;4(23):834136.
27. Darbalaei S, Zhang XL,Wang NX, et al. Effects of aprepitant on the
pharmacokinetics of imatinib and its main metabolite in rats. Die
Pharmazie . 2018;73(6): 329-334.
28. Vasconcelos FC, Bonecker ST, de Souza PS, et al. Age, gender and
efflux transporter activity influence imatinib efficacy in chronic
myeloid leukemia patients. Leukemia Res . 2019;82: 33-35.
29. Valsangkar N, Sehdev A, Misra S, Zimmers TA, O’Neil BH, Koniaris LG.
Current management of gastrointestinal stromal tumors: Surgery, current
biomarkers, mutations, and therapy. Surgery.2015;158(5):1149-1164.
30. Li J, Gong JF, Li J, Gao J, Sun NP, Shen L. Efficacy of imatinib
dose escalation in Chinese gastrointestinal stromal tumor patients.World J Gastroenterol . 2012;18(7):698-703.
31. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized,
intergroup trial assessing imatinib mesylate at two dose levels in
patients with unresectable or metastatic gastrointestinal stromal tumors
expressing the kit receptor tyrosine kinase: S0033. J Clin Onco .
2008;26(4):626-32.
32. Yoo C, Ryu MH, Jo J, Park I, Ryoo BY, Kang YK. Efficacy of Imatinib
in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated
Gastrointestinal Stromal Tumors. Cancer Res Treat .
2016;48(2):546-52.
33. Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive
heart failure in gastrointestinal stromal tumor and other sarcoma
patients receiving imatinib mesylate. Cancer . 2010;116(1):184-92.
34. Ben Ami E, Demetri GD. A safety evaluation of imatinib mesylate in
the treatment of gastrointestinal stromal tumor. Expert Opin Drug
Saf . 2016;15(4): 571-578.